Literature DB >> 15905121

Changes in natural killer T cells subsets during therapy in type C hepatitis and hepatocellular carcinoma.

Akihiko Okumura1, Tetsuya Ishikawa, Tadashi Maeno, Ken Sato, Minoru Ayada, Naoki Hotta, Taeko Yamauchi, Yoshitaka Fukuzawa, Shinichi Kakumu.   

Abstract

Natural killer T (NKT) cells share features of both classical T cells and NK cells. NKT are heterogenous populations, and recognize glycolipids associated with CD1d molecule. We investigated Th1/Th2 cytokine production as well as frequency and phenotype of circulating NKT cells in 14 healthy subjects and in patients during therapy with type C chronic hepatitis (CH; 14 cases) and hepatocellular carcinoma (HCC; 13 cases). Peripheral blood mononuclear cells (PBMC) were obtained before and 2 weeks later interferon (IFN)/ribavirin and radiofrequency ablation therapy for CH and HCC, respectively. PBMC were cultured for 10 days with alpha-galactosylceramide (alpha-GalCer) and interleukin-2 (IL-2). Frequencies and IFN-gamma/IL-4 production of NKT cells were analyzed using flow cytometry. Intrahepatic lymphocytes were analyzed in seven CH patients with liver biopsy specimen. Prevalence of circulating Valpha24+CD3+ T cells was 0.9+/-0.9% of PBMC for controls and increased to 8.5+/-8.9% (p<0.001) in response to alpha-GalCel. Similar frequency and expansion were noted in CH. The frequency increased during therapy. The prevalence in HCC tended to be high compared to controls and response to alpha-GalCel was well. Although frequency of Valpha24+Vbeta11+CD3+ T cells was low in all groups, the distribution pattern was similar to Valpha24+Vbeta11-CD3+ T cells. Prevalence of CD56+CD3+ T cells was low independent of therapy in CH (2-3%) compared to 5.0+/-4.0% of controls, although response to alpha-GalCel was not impaired. IFN-gamma production of Valpha24+CD3+ T cells did not differ among groups, but became greater after treatment in contrast to lowered IL-4 production. Frequencies of NKT populations were higher in liver than in peripheral blood. Our study suggests that CD1d-reactive T cells have distinct distribution in different populations and therapy for patients alters cytokine response of NKT cells.

Entities:  

Year:  2005        PMID: 15905121     DOI: 10.1016/j.hepres.2005.02.008

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  9 in total

1.  CD56+ T cells inhibit HIV-1 infection of macrophages.

Authors:  Wei Hou; Li Ye; Wen-Zhe Ho
Journal:  J Leukoc Biol       Date:  2012-05-16       Impact factor: 4.962

2.  Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro.

Authors:  Lucy Golden-Mason; Andrea L Cox; Jessica A Randall; Linling Cheng; Hugo R Rosen
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 3.  Potentiality of immunotherapy against hepatocellular carcinoma.

Authors:  Nobuhiro Tsuchiya; Yu Sawada; Itaru Endo; Yasushi Uemura; Tetsuya Nakatsura
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

4.  Activation of natural killer cells by hepatitis C virus particles in vitro.

Authors:  M M S Farag; K Weigand; J Encke; F Momburg
Journal:  Clin Exp Immunol       Date:  2011-06-17       Impact factor: 4.330

5.  Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users.

Authors:  Li Ye; Xu Wang; David S Metzger; Eric Riedel; Luis J Montaner; Wenzhe Ho
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

6.  CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes.

Authors:  Li Ye; Xu Wang; Shihong Wang; Yanjian Wang; Li Song; Wei Hou; Lin Zhou; He Li; Wenzhe Ho
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

7.  KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection.

Authors:  Jia M Wang; Yong Q Cheng; Lei Shi; Ruo S Ying; Xiao Y Wu; Guang Y Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

8.  PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma.

Authors:  Longxiang Tao; Shanshan Wang; Guijie Kang; Shanyue Jiang; Wenwei Yin; Lu Zong; Jing Li; Xuefu Wang
Journal:  Oncoimmunology       Date:  2021-11-09       Impact factor: 8.110

9.  Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections.

Authors:  Jin S Im; Tae-Jin Kang; Seong-Beom Lee; Chi-Hong Kim; Sang-Haak Lee; Manjunatha M Venkataswamy; Evan R Serfass; Bing Chen; Petr A Illarionov; Gurdyal S Besra; William R Jacobs; Gue-Tae Chae; Steven A Porcelli
Journal:  Clin Immunol       Date:  2008-03-04       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.